
Cat Vaccine Market Report 2026
Global Outlook – By Vaccine Type (Modified Or Attenuated Live, Inactivated, Other Vaccine Types), By Disease Type (Feline Leukemia, Feline Panleukopenia, Feline Respiratory Diseases, Feline Rabies, Other Disease Types), By Technology (Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Deoxyribonucleic Acid (DNA) Vaccines, Recombinant Vaccines), By Route Of Administration (Injectables, Intranasal, Oral), By Distribution Channel (Veterinary Clinics, Pet Stores, Online Retailers) – Market Size, Trends, Strategies, and Forecast to 2035
Cat Vaccine Market Overview
• Cat Vaccine market size has reached to $1.26 billion in 2025 • Expected to grow to $1.93 billion in 2030 at a compound annual growth rate (CAGR) of 8.9% • Growth Driver: Rising Zoonotic Diseases Fuel The Growth Of The Cat Vaccine Market • Market Trend: Innovations In Cat Vaccines NOBIVAC NXT Utilizes RNA-Particle Technology For Enhanced Feline Disease Protection • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.What Is Covered Under Cat Vaccine Market?
A cat vaccine is a biological preparation designed to protect cats from infectious diseases by stimulating their immune system to recognize and fight off specific pathogens. These vaccines contain weakened or inactivated forms of viruses or bacteria that cause diseases, prompting the cat's immune system to produce antibodies without causing illness. The main types of cat vaccines are modified or attenuated live, inactivated, and others. Modified or attenuated live vaccines are created by weakening the pathogen that causes disease so it cannot cause illness in cats. The various disease types include feline leukemia, feline panleukopenia, feline respiratory diseases, feline rabies, and others. The various technologies include attenuated live vaccines, conjugate vaccines, inactivated vaccines, subunit vaccines, toxoid vaccines, deoxyribonucleic acid (DNA) vaccines, recombinant vaccines with various routes of administration that include injectables, intranasal, and oral. These are distributed by various distribution channels such as veterinary clinics, pet stores, and online retailers.
What Is The Cat Vaccine Market Size and Share 2026?
The cat vaccine market size has grown strongly in recent years. It will grow from $1.26 billion in 2025 to $1.38 billion in 2026 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to rising incidence of feline infectious diseases, limited availability of advanced vaccines, growth of pet ownership, expansion of veterinary clinics, government vaccination initiatives.What Is The Cat Vaccine Market Growth Forecast?
The cat vaccine market size is expected to see strong growth in the next few years. It will grow to $1.93 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to technological advancements in vaccine development, increasing demand for recombinant and dna vaccines, rising awareness of preventive healthcare in pets, expansion of online veterinary services, integration of ai and data analytics in disease monitoring. Major trends in the forecast period include increased adoption of core vaccination programs, growth of recombinant and dna vaccines, expansion of veterinary healthcare services, rising awareness of pet health and disease prevention, integration of telemedicine and remote monitoring in veterinary care.Global Cat Vaccine Market Segmentation
1) By Vaccine Type: Modified Or Attenuated Live, Inactivated, Other Vaccine Types 2) By Disease Type: Feline Leukemia, Feline Panleukopenia, Feline Respiratory Diseases, Feline Rabies, Other Disease Types 3) By Technology: Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Deoxyribonucleic Acid (DNA) Vaccines, Recombinant Vaccines 4) By Route Of Administration: Injectables, Intranasal, Oral 5) By Distribution Channel: Veterinary Clinics, Pet Stores, Online Retailers Subsegments: 1) By Modified Or Attenuated Live: Feline Viral Rhinotracheitis (FVR) Vaccine, Feline Calicivirus (FCV) Vaccine, Feline Panleukopenia (FPV) Vaccine 2) By Inactivated: Inactivated Feline Leukemia Virus (FeLV) Vaccine, Inactivated Feline Infectious Peritonitis (FIP) Vaccine 3) By Other Vaccine Types: Recombinant Vaccines, DNA Vaccines, Subunit Vaccines, Combination VaccinesWhat Is The Driver Of The Cat Vaccine Market?
The increasing prevalence of zoonotic diseases is expected to propel the growth of the cat vaccine market going forward. Zoonotic diseases are infections that can pass from animals to humans, caused by pathogens such as bacteria, viruses, fungi, or parasites. These diseases can spread through direct contact, vectors, or contaminated environments. The common zoonotic diseases are lyme disease, rabies, toxoplasmosis, salmonellosis, brucellosis, and more. The increasing prevalence of zoonotic diseases is due to climate change, antibiotic resistance, and illegal and legal wildlife trade. Cat vaccines control zoonotic diseases by reducing the risk of transmission from cats to humans by vaccinating cats against diseases such as toxoplasmosis and cat scratch fever. This proactive approach helps mitigate zoonotic diseases' impact on human health, supports public health efforts, and ensures a healthier environment for pets and their owners. For instance, in February 2024, according to a report published by the Government of the United Kingdom, a UK-based government agency, in the fourth quarter of 2023, England reported 335 confirmed cases of Lyme disease, an increase from the 273 cases recorded during the same period in 2022. Therefore, the increasing zoonotic diseases drive the cat vaccine industry.Key Players In The Global Cat Vaccine Market
Major companies operating in the cat vaccine market are Merck & Co. Inc., Boehringer Ingelheim International GmbH, Zoetis Inc., MSD Animal Health, Elanco Animal Health Incorporated, Ceva Santé Animale, Virbac, HIPRA Corporation, Bioveta AS, Biogénesis Bagó SA, Torigen Pharmaceuticals Inc., Vetoquinol SA, Phibro Animal Health Corporation, IDT Biologika GmbH, Vaxxinova BV, Colorado Serum Company, Huvepharma NV, Bimeda Biologicals, CAVAC, Kyoto Biken Laboratories, Avimex Animal Health, Ringpu Biology, Wuhan Keqian Biology, Pulike Biological Engineering, Chengdu Kanghua Biological Products, Yebio, FATROGlobal Cat Vaccine Market Trends and Insights
Major companies operating in the cat vaccine market are focused on developing innovative products such as NOBIVAC NXT vaccines that utilize state-of-the-art Ribonucleic acid (RNA)-particle technology to enhance immune responses, improve vaccine efficacy, and provide targeted protection against feline diseases. State-of-the-art Ribonucleic acid (RNA)-particle technology is an innovative approach that uses RNA molecules encapsulated in nanoparticles to deliver genetic instructions to cells, prompting them to produce specific proteins that stimulate a targeted immune response. For instance, in June 2024, MSD Animal Health Inc., a US-based pharmaceutical company, launched The NOBIVAC NXT Rabies portfolio consists of NOBIVAC NXT Feline-3 Rabies and NOBIVAC NXT Canine-3 Rabies, a comprehensive vaccination solution designed to provide effective protection against rabies in cats and dogs. The NOBIVAC NXT vaccines are formulated without adjuvants and preservatives, enhancing their safety profile while maintaining efficacy. The vaccines stimulate both humoral (antibody-mediated) and cell-mediated immune responses, providing comprehensive protection against the rabies virus.What Are Latest Mergers And Acquisitions In The Cat Vaccine Market?
In September 2024, Boehringer Ingelheim Group, a Germany-based pharmaceutical company, acquired Saiba Animal Health AG for an undisclosed amount. This acquisition marked Boehringer Ingelheim's strategic move to expand its portfolio by incorporating Saiba's expertise in providing cat vaccines. Saiba Animal Health AG is a Switzerland-based company that offers cat vaccines.Regional Outlook
North America was the largest region in the cat vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, SpainWhat Defines the Cat Vaccine Market?
The cat vaccine market consists of sales of the bordetella vaccine, rabies vaccine, and feline immunodeficiency virus (FIV) vaccine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.Cat Vaccine Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $1.38 billion |
| Revenue Forecast In 2035 | $1.93 billion |
| Growth Rate | CAGR of 9.2% from 2026 to 2035 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 - 2035 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2035 |
| Segments Covered | Vaccine Type, Disease Type, Technology, Route Of Administration, Distribution Channel |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, ... |
| Key Companies Profiled | Merck & Co. Inc., Boehringer Ingelheim International GmbH, Zoetis Inc., MSD Animal Health, Elanco Animal Health Incorporated, Ceva Santé Animale, Virbac, HIPRA Corporation, Bioveta AS, Biogénesis Bagó SA, Torigen Pharmaceuticals Inc., Vetoquinol SA, Phibro Animal Health Corporation, IDT Biologika GmbH, Vaxxinova BV, Colorado Serum Company, Huvepharma NV, Bimeda Biologicals, CAVAC, Kyoto Biken Laboratories, Avimex Animal Health, Ringpu Biology, Wuhan Keqian Biology, Pulike Biological Engineering, Chengdu Kanghua Biological Products, Yebio, FATRO |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |
